The pharmacokinetics of intravenous fenoldopam in healthy,awake cats |
| |
| Authors: | K. E. O'Neill M. A. Labato M. H. Court |
| |
| Affiliation: | 1. St. Francis Veterinary Specialists, Decatur, GA, USA;2. Cummings School of Veterinary Medicine at Tufts University, North Grafton, MA, USA;3. College of Veterinary Medicine at Washington State University, Pullman, WA, USA |
| |
| Abstract: | Fenoldopam is a selective dopamine‐1 receptor agonist that improves diuresis by increasing renal blood flow and perfusion and causing peripheral vasodilation. Fenoldopam has been shown to induce diuresis and be well‐tolerated in healthy cats. It is used clinically in cats with oliguric kidney injury at doses extrapolated from human medicine and canine studies. The pharmacokinetics in healthy beagle dogs has been reported; however, pharmacokinetic data in cats are lacking. The goal of this study was to determine pharmacokinetic data for healthy, awake cats receiving an infusion of fenoldopam. Six healthy, awake, client‐owned cats aged 2–6 years old received a 120‐min constant rate infusion of fenoldopam at 0.8 μg/kg/min followed by a 20‐min washout period. Ascorbate stabilized plasma samples were collected during and after the infusion for the measurement of fenoldopam concentration by HPLC with mass spectrometry detection. This study showed that the geometric mean of the volume of distribution, clearance, and half‐life (198 mL/kg, 46 mL/kg/min, and 3.0 mins) is similar to pharmacokinetic parameters for humans. No adverse events were noted. Fenoldopam at a constant rate infusion of 0.8 μg/kg per min was well tolerated in healthy cats. Based on the results, further evaluation of fenoldopam in cats with kidney disease is recommended. |
| |
| Keywords: | |
|
|
